SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE
14D-9
SOLICITATION/RECOMMENDATION STATEMENT
UNDER SECTION 14(d)(4) OF THE
SECURITIES EXCHANGE ACT OF 1934
Sagent
Pharmaceuticals, Inc.
(Name of Subject Company)
Sagent Pharmaceuticals, Inc.
(Names of Person(s) Filing Statement)
Common Stock,
par value $0.01 per share
(Title of Class of Securities)
78669210
(CUSIP Number
of Class of Securities)
Allan Oberman
Chief
Executive Officer
Sagent Pharmaceuticals, Inc.
1901 N. Roselle Road, Suite 700
Schaumburg, Illinois 60195
(847) 908-1600
(Name,
Address and Telephone Number of Person Authorized to Receive
Notice and Communications on Behalf of the Person(s) Filing Statement)
Copies To:
George P. Stamas
William
B. Sorabella
Alexander D. Fine
Kirkland & Ellis LLP
601 Lexington Avenue
New
York, New York 10022
(212) 446-4800
x
|
|
Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.
|
This Schedule 14D-9 filing consists of certain communications related to the proposed acquisition
of Sagent Pharmaceuticals, Inc. (
Sagent
) by Nichi-Iko Pharmaceutical Co., Ltd. (
Nichi-Iko
) pursuant to the terms and subject to the conditions of an Agreement and Plan of Merger, dated as of July 10, 2016,
by and among Sagent, Nichi-Iko and Shepard Vision, Inc., a wholly-owned subsidiary of Nichi-Iko.
This Schedule 14D-9 consists of the
following document: a letter from Nichi-Ikos Chief Executive Officer to Sagents employees.
July 12, 2016
Dear
Sagent Team Members,
On behalf of the Nichi-Iko Board and management, I want to emphasize how excited we are to have Sagent Pharmaceuticals join our
company. Our goal is to unite two market leaders, building on our strengths to achieve our growth objectives and become a top ten global pharmaceutical company.
Sagent and Nichi-Iko share many similarities anchored by a customer-centric philosophy, focus on quality and passion for meeting the needs of patients. Our
business philosophy runs in parallel to Sagents to focus on gaining market share, expanding supply chain capacity and penetrating new, international markets. Furthermore, we recognize that Sagents dedicated employees are its greatest
asset, and we look forward to working with and learning from all of you. Our strategy is aimed at business expansion and we recognize the importance that all Sagent employees will play in helping us meet this goal.
Succeeding in the U.S. market is a top priority for Nichi-Iko, and we believe adding the Sagent team is the ideal way to accelerate our international growth
strategy, for many reasons, including:
|
|
|
Our two companies are highly complementary. Nichi-Iko and Sagent have little overlap in terms of our offerings or product portfolios.
|
|
|
|
Through the combination, Nichi-Iko will gain a sales platform in the U.S. while Sagent will gain a supplier and sales team in Japan and Southeast Asia.
|
|
|
|
Importantly, we also share similar core values and focus on quality and we are firmly committed to maintaining a work environment that respects Sagents current culture.
|
Im very excited about the future of this company and about the opportunities ahead that our two great organizations will create together.
Sincerely,
Yuichi Tamura
CEO
Nichi-Iko Pharmaceutical Co., Ltd.
Important Information
The Tender Offer for the outstanding shares of Sagent common stock has not yet commenced. This communication is for informational purposes only and is neither
an offer to purchase nor a solicitation of an offer to sell shares of Sagent common stock. The solicitation and offer to buy shares of Sagent common stock will only be made pursuant to the Tender Offer materials that Nichi-Iko and its acquisition
subsidiary intends to file with the U.S. Securities and Exchange Commission (the SEC). At the time the Tender Offer is commenced, Nichi-Iko will file a Tender Offer statement on Schedule TO with the SEC, and Sagent will file a
solicitation/recommendation statement on Schedule 14D-9 with respect to the Tender Offer. SAGENTS STOCKHOLDERS ARE ADVISED TO READ THE SCHEDULE TO (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND OTHER OFFER DOCUMENTS) AND
THE SCHEDULE 14D-9, AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BEFORE THEY MAKE ANY DECISION WITH RESPECT TO THE TENDER OFFER, BECAUSE THEY WILL CONTAIN
IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES THERETO. Both the Tender Offer statement and the solicitation/recommendation statement will be mailed to Sagents stockholders free of charge. Investors and stockholders may
obtain free copies of the Schedule TO and Schedule 14D-9, as each may be amended or supplemented from time to time, and other documents filed by the parties (when available) at the SECs web site at www.sec.gov or by contacting Michael Ward,
the Companys Chief Legal Officer and Corporate Secretary either by telephone at (847) 908-1600 or by e-mail at
legal@sagentpharma.com
.
Cautionary Statement Regarding Forward-Looking Statements
Any statements made in this communication that are not descriptions of historical facts, including those relating to the anticipated timing, duration, closing
conditions, completion and success of the proposed transaction, and the potential effects and benefits of the transaction on both Nichi-Iko and Sagent and any other statements about future expectations, are forward-looking statements that are based
on managements beliefs, certain assumptions and current expectations, and should be evaluated as such. Forward-looking statements also include statements that may relate to Nichi-Ikos or Sagents plans, objectives, strategies,
goals, future events, future financial and operating performance, and other information that is not historical information. These statements may be identified by their use of forward-looking terminology such as the words anticipate,
expect, suggest, plan, believe, intend, estimate, target, project, could, should, may, will,
would, continue, forecast, and other similar expressions. Forward-looking information is based on, among other things, opinions, assumptions, estimates and analyses that, while considered reasonable by us at the
date the forward-looking information is provided, are inherently subject to significant risks, uncertainties, contingencies and other factors that may cause actual results and events to differ materially from those expressed or implied by the
forward-looking information. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward looking statements. These risks and uncertainties include, but are not limited
to, general economic, business and market conditions, the satisfaction of the conditions to the consummation of the proposed transaction, the timing of the completion of the proposed transaction and the potential impact of the announcement or
consummation of the proposed transaction on Sagents and Nichi-Ikos important relationships, including with employees, suppliers and customers. For a further description of the risks and uncertainties that could cause actual results to
differ from those expressed in these forward-looking statements, as well as risks relating to the business of Sagent in general, see Sagents Form 10-K for the year ended December 31, 2015, subsequent reports on Form 10-Q and 8-K, and
other filings by the Company with the SEC. Further, forward-looking statements speak only as of the date they are made, and neither Nichi-Iko nor Sagent undertakes any obligation to update or revise any forward-looking statements to reflect changed
assumptions, the occurrence of unanticipated events or changes to future operating results over time, except as required by law. All written and oral forward-looking statements attributable to us or persons acting on our behalf are qualified in
their entirety by these cautionary statements.
Sagent (NASDAQ:SGNT)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Sagent (NASDAQ:SGNT)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024